Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer

British Journal of Cancer

Volumn 109, Issue 5, 2013, Pages 1079-1084

  Omlin, A ^a   J Pezaro, C ^a   Zaidi, S ^a   Lorente, D ^a   Mukherji, D ^a   Bianchini, D ^a   Ferraldeschi, R ^a   Sandhu, S ^a   Dearnaley, D ^b   Parker, C ^b   Van As, N ^b   De Bono, J S ^a   Attard, G ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

castration resistant prostate cancer; abiraterone; treatment sequencing; diethylstilboestrol

Indexed keywords

ABIRATERONE; CABAZITAXEL; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DEMOGRAPHY; DRUG DOSE SEQUENCE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIETHYLSTILBESTROL; DISEASE PROGRESSION; ESTROGENS, NON-STEROIDAL; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TAXOIDS; TREATMENT OUTCOME;

EID: 84883743636     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.446     Document Type: Article

References (26)

1. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27(23): 3742-3748.
2. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28): 4563-4571.
3. Bosset PO, Albiges L, Seisen T, de la Motte Rouge T, Phe V, Bitker MO, Roupret M (2012) Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int 110: E826-E829.
4. Carden CP, Raynaud FI, Jones RL, Riggs SB, Martins V, Oommen N, McIntosh D, Lee G, De Bono JS, Kabbinavar FF (2008) Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer. J Clin Oncol 26(suppl): abstract 5168.
5. Clemons J, Glode LM, Gao D, Flaig TW (2011) Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol 31: 198-204.
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman Jr. OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 364(21): 1995-2005.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247.
8. Fleming MT, Morris MJ, Heller G, Scher HI (2006) Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 3(12): 658-667. (Pubitemid 44843124)
9. Geier R, Adler S, Rashid G, Klein A (2010) The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells. Prostate 70(12): 1307-1312.
10. Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168(1): 9-12.
11. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C (2013) Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24(7): 1807-1812.
12. Malkowicz SB (2001) The role of diethylstilbestrol in the treatment of prostate cancer. Urology 58(2 Pt 1): 108-113. (Pubitemid 32743424)
13. Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN (2005) Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Urol Int 75(3): 217-221. (Pubitemid 41433869)
14. Montgomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R, Stahl WL (2005) Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. The Prostate 65(2): 141-150. (Pubitemid 41362281)
15. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN (2013) Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24(7): 1802-1807.
16. Parmar H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV (1985) Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 2(8466): 1201-1205. (Pubitemid 16203839)
17. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28(9): 1489-1495.
18. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE (2012) Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 368: 138-148.
19. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28(9): 1481-1488.
20. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 367(13): 1187-1197.
21. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7): 1148-1159.
22. Scott WW, Benjamin JA (1945) The role of bilateral orchiectomy in the treatment of carcinoma of the prostate gland. Bull N Y Acad Med 21(6): 307-332.
23. Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P, Tranter N, O'Brien N, McFaul S, Oliver T (2011) A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer 104(4): 620-628.
24. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ (1998) A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 52(2): 257-260. (Pubitemid 28357829)
25. Wang H, Li J, Gao Y, Xu Y, Pan Y, Tsuji I, Sun ZJ, Li XM (2010) Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor. Asian J Androl 12(4): 535-547.
26. Wilkins A, Shahidi M, Parker C, Gunapala R, Thomas K, Huddart R, Horwich A, Dearnaley D (2012) Diethylstilbestrol in castration-resistant prostate cancer. BJU Int 110: E727-E735.